Popular Article

OPEN ACCESS

Nanotechnology-Driven Antimicrobial Strategies: Pharmacological Insight

Riya Talariya[1], Shweta Singh[1], Anand Mohan Mishra[1], Ilavarasan S[1], Raushan Kumar Singh[2], Meemansha Sharma[1]*

[1]Pharmacology and Toxicology Division, ICAR-Indian Veterinary Research Institute Izatnagar-243122, Bareilly, Uttar Pradesh, India
[2]Krishi Vigyan Kendra, Budaun-243639, Sardar Vallabhbhai Patel University of Agriculture and Technology, Meerut, Uttar Pradesh, India

ARTICLE HISTORY

Received: October 10, 2025
Accepted: October 10, 2025
Published: November 1, 2025

Abstract

The rapid emergence of inactivity towards the antimicrobial necessitates the invention of innovative remedies beyond the conventional treatment sources. Presently, it possible to create antimicrobial nanoparticles with special physicochemical and biological characteristics, nanotechnology provides a promising platform to address this issue. Antimicrobial nanoparticles, typically lesser than100 nm in dimension, include metal, metal oxide, polymeric, and lipid-based systems that exhibit wide ranging action and lower tendency to acquire resistance. Strong interactions with intracellular targets and microbial membranes are made possible by their adjustable surface properties and high contact volume to area ratio. Through a variety of additive mechanisms, such as cell wall destruction, reactive oxygen compounds generation, inhibition of enzymes, genome interference, biofilm rupturing, and host immune response alteration, these nanoparticles produce antimicrobial effects. In addition, antimicrobial nanoparticles demonstrate favourable pharmacokinetic and pharmacodynamic profiles, enabling targeted delivery, sustained release, and synergistic activity with existing antibiotics. In both medical as well as veterinary contexts, these characteristics make them very effective against biofilm-driven bacteria that are multidrug-resistant. However, concerns related to toxicity, tissue accumulation, immune reactions, and environmental impact remain significant barriers to translation. This study offers a thorough pharmacological background on anti-microbial nanoparticles, emphasizing their therapeutic uses, PK-PD issues, their means of action, and safety concerns. Overall, antimicrobial nanoparticles represent a transformative and versatile approach for combating resistant infections and addressing the growing global burden of antimicrobial resistance.

***Corresponding author's email:** *sharmameemansha98@gmail.com*

KEYWORDS: Antimicrobial nanoparticles, Mechanism of antimicrobial nanoparticles, Pharmacokinetics and pharmacodynamics, Nanotoxicity

INTRODUCTION

In the face of escalating global health challenges posed by antibiotic resistance, the exploration of alternative and innovative strategies has become imperative. Nanotechnology presents intriguing ways to fight microbial diseases because of its special capacity to alter stuff at molecular and atomic scales. A growing area in this research is antimicrobial nanoparticles, which are distinguished by their multifaceted qualities, wide-ranging action, and decreased risk of building resistance. Antimicrobial nanoparticles are synthetic materials that are usually smaller than 0.1micrometer in size. They include a wide variety of materials, including metallic and their oxides, synthetic polymers, and lipid-centered complexes (Figure 1) (Mondal et al., 2024). Pharmacological potential of antimicrobial nanoparticles is particularly compelling, offering targeted delivery, sustained release, and advantageous outcomes once paired alongside classical antimicrobials (Gao et al., 2018). In addition to addressing the drawbacks of conventional antibiotics, this novel strategy creates new treatment options for biofilm-related ailments, novel developing pathogens, and MDR infectious agents. (Parvin et al., 2025). The fundamental mechanisms of sterilizing action, the many kinds of tiny particles of nano origins, and their clinical applicability are all covered in this review. We hope to present a thorough pharmacological view of the revolutionary promise of antimicrobial nanoparticles in contemporary medical care by emphasizing the most present progress and obstacles to this area.



Fig. 1: Diagrammatic illustration of the main categories of nanoparticles according to their makeup.

MECHANISM OF ANTIMICROBIAL NANOPARTICLES TO COMBAT MICROBIAL INFECTIONS

As shown in Figure 2, antimicrobial nanomaterials erode the cell membranes, induce oxidative strain, suppress vital proteins, produce interference with genetic level and disrupt the building of biofilms in order to achieve their protective impacts. Their synergy with antibiotics and ability to modulate immune responses further enhance their therapeutic potential.



Fig. 2: Illustration depicting the various ways that microbial nanoparticles fight infectious diseases

Disruption of microbial membranes: Because of their substantial surface radiation and charging characteristics, nanoparticles interact strongly with outer cellular membranes of living microbes (Chen et al., 2025). Electrical instability and broken structures result from nanoparticles with positive charge adhering to negatively energized microbiological wall.

Free radical emission: By producing ROS (reactive oxygen species) like oxidant anions, peroxide of hydrogen, and radicals of hydroxyl, a variety of microscopic particles, such as TiO_2, zinc oxide (ZnO), and silver, cause oxidative destruction. Mortality of cells results from these reacting molecules that induce harm to cellular protein, fat and genetic code (Wang et al., 2017). ROS-induced oxidative injury is especially powerful in undermining microbial defence systems.

Protein denaturation and enzyme inhibition: Metal-based nanoparticles release ions (e.g., Ag^+, Cu^{2+}) that bind to thiol groups in microbial proteins, causing denaturation and functional loss. This disrupts critical processes like respiration and the movement of nutrients (Jiang et al., 2024). Additionally, nanoparticles interfere with key enzymes, effectively shutting down microbial metabolic pathways (Ameh et al., 2022).

Interaction with genetic material: Certain nanomaterials enter into the cells of bacteria and come into direct contact with their genomes. For instance, gold & silver nano formulations bind to DNA, inhibiting replication and transcription (Sakthi et al., 2022; Moreno Ruiz et al., 2023).

Anti-biofilm activity: Biofilms protect microbes from conventional treatments, but nanoparticles can counteract these defences. By disrupting quorum sensing, nanoparticles prevent biofilm formation. They can attack entrenched bacteria by penetrating biofilm matrices due to their tiny dimensions (Mu et al., 2016). These miniatures also degrade extracellular polymeric substances (EPS), destabilizing biofilm structures and enhancing antimicrobial effectiveness (Wang et al., 2020)**.**

Immune modulation: These minules enhance the host immune response by activating macrophages and neutrophils, boosting phagocytosis and cytokine production. Additionally, nanoparticles with anti-inflammatory properties mitigate tissue damage caused by excessive inflammation during infections (Huang et al., 2024).

PHARMACOKINETIC AND PHARMACODYNAMICS OF ANTIMICROBIAL NANOPARTICLES

The pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial nanoparticles are central to their therapeutic efficacy and safety. The absorption of nanoparticles involves more intricate mechanisms compared to small molecules. When administered orally, nanoparticles can be taken up through paracellular pathways, transcytosis, or by M cells in the gastrointestinal tract. In contrast, nanoparticles delivered via subcutaneous, intramuscular, or inhalation routes are primarily absorbed by macrophages and through lymphatic uptake. The mode of action like opsonization, corona protein synthesis, absorption by phagocytic system of monocytes, the increased absorptivity, retention and movement through lymph channel represent a few of the transport processes that affect the internal spread of nanoparticles (Mathur et al., 2018). The metabolism of nanoparticles occurs through both enzymatic and non-enzymatic pathways. Excretion primarily takes place via renal or hepatobiliary routes; however, suboptimal design may result in tissue accumulation and associated toxicity (Jain & Bhise, 2025). PD mechanisms include direct microbial interactions like disruption of membrane, production of ROS and interaction with genetic material and protein (Aflakian et al., 2023; Mondal et al., 2024). Nanoparticles often show dose-dependent effects with low minimum inhibitory concentrations (MIC), enhancing their antimicrobial potency. Synergistic effects with traditional antibiotics allow for overcoming microbial resistance (Mazur,2020). Importantly, nanoparticles display both time-dependent and concentration-dependent killing profiles, depending on their composition and release mechanisms (Alikhani et al., 2025). The integration of PK and PD insights facilitates the optimization of nanoparticle formulations, ensuring maximum efficacy, targeted delivery, and minimal toxicity (Lee et al., 2019). This makes antimicrobial nanoparticles a promising solution in combating multidrug-resistant infections and complex microbial challenges.

ROLE OF NANOPARTICLES AGAINST INFECTION RESISTANCE TO DRUGS

Nanoparticles play a transformative role in combating drug-resistant pathogens by addressing the limitations of conventional antimicrobial therapies. Drug resistance results from mechanisms that reduce the effectiveness of conventional antibiotics, such as pumps that regulate outward movement of ligands, degradation by proteinases, and genetic mutations (Vivekanandan et al., 2025; AlQurashi et al., 2025). Nanocrystals offer an array of ways to address such issues due to its distinct unique characteristics. They are capable of killing germs at points of infection by penetrating microbial membranes and biofilms due to their minute structure. Unlike traditional antibiotics, nanoparticles behave like variety of ways, including tearing outer shell, making radicals, while destroying proteogenomic material (Sharmin et al., 2021; Chakraborty et al., 2022; Olawade et al., 2024). Such many strategies lessen the possibility of resilience that may emerge. Furthermore, through combinatorial actions like enclosing drugs for tailored and longer-lasting release or blocking resistance-generating pathways like pumps that regulate efflux, nanomaterials improve the effectiveness of currently available medicines. Lipid or polymer-based formulations and nanosize particles made up from metals have demonstrated strong efficacy against bacteria, bacteria and others microbial agents fungi that are resilient to many drugs (Wang et al., 2025; Ribeiro et al., 2022; Mishra et al., 2022). In majority, these nanoformulations work well to prevent quorum sensing and fight illnesses linked to biological films. Their versatility extends to functionalization, where nanoparticles are tailored with ligands or coatings to selectively target pathogens, minimizing host toxicity (Qais et al., 2021; Afrasiabi et al., 2024). By addressing both intrinsic and acquired resistance mechanisms, nanoparticles represent a promising avenue for combating multidrug-resistant pathogens, ensuring improved treatment outcomes and reducing the prevalence of AMR.

TOXICITY ALONG WITH SAFETY CONCERN

The practical application of antimicrobial nanostructures presents serious safety and toxicity issues that need to be resolved for their clinical and environmental applications (Fig. 3). Although their extreme sensitivity as well as tiny stature serve as advantages for the killing of bacteria, they might additionally inadvertently attach to immune system cells and tissues. Overproduction of oxides radicals produced by metal-based nanoparticles can lead to chronic inflammation, oxidant strain, and lead to degradation of biological components. Organ toxicity may arise from the accumulation of nanoscale preparation in internal tissues as a result of insufficient clearance (Xuan et al., 2023; Yu et al., 2020; Min et al., 2023). Additionally, prolonged nanostuff exposure can disrupt the gut microbiota or induce immune hypersensitivity (Perez et al., 2021; Landsiedel et al., 2022; Hofer et al., 2022). Environmental concerns also arise from nanoparticles persistence, which can negatively affect ecosystems by disrupting microbial communities or accumulating in aquatic organisms. Techniques including surface customization, regulated release products, and biocompatible films are used to improve selectivity and lessen unwanted effects in order to lessen these dangers (Sun et al., 2022). Establishing safe dosage thresholds and long-term consequences requires thorough toxicological examinations, combining laboratory testing as well as preclinical investigations. To ensure the secure creation and utilization of antimicrobial nanotechnology while optimizing their therapeutic potential, regulations and standardized testing procedures are essential.



Fig. 3: A diagrammatic representation of toxicological consequences of nanoparticles

FUTURE OUTLOOK & CONCLUSION

The destiny of antimicrobial nanoparticles lies in their advancement as targeted, efficient, and safe alternatives to conventional therapies, especially against multidrug-resistant pathogens. Innovations in nanotechnology, such as functionalization and controlled delivery, will enhance their therapeutic potential while minimizing toxicity. Integration into clinical practice requires rigorous research, regulatory approvals, and eco-friendly designs. Overall, antimicrobial nanoparticles hold transformative promise for revolutionizing infection management and addressing global antimicrobial resistance challenges.

ACKNOWLEDGMENT

Director IVRI is acknowledged by the authors.

CONFLICT OF INTEREST

None

REFERENCES

Aflakian, F., Mirzavi, F., Aiyelabegan, H.T., Soleimani, A., Navashenaq, J.G., Karimi-Sani, I., Zomorodi, A.R. and Vakili-Ghartavol, R., (2023). Nanoparticles-based therapeutics for the management of bacterial infections: A special emphasis on FDA approved products and clinical trials. *European Journal of Pharmaceutical Sciences*, 188, p.106515.

Afrasiabi, S., & Partoazar, A. (2024). Targeting bacterial biofilm-related genes with nanoparticle-based strategies. *Frontiers in Microbiology*, 15, 1387114.

Alikhani, M. S., Nazari, M., & Hatamkhani, S. (2025). Enhancing antibiotic therapy through comprehensive pharmacokinetic/pharmacodynamic principles. *Frontiers in Cellular and Infection Microbiology*, 15, 1521091.

AlQurashi, D. M., AlQurashi, T. F., Alam, R. I., Shaikh, S., & Tarkistani, M. A. M. (2025). Advanced nanoparticles in combating antibiotic resistance: current innovations and future directions. *Journal of Nanotheranostics*, 6(2), 9.

Ameh, T., Gibb, M., Stevens, D., Pradhan, S. H., Braswell, E., & Sayes, C. M. (2022). Silver and copper nanoparticles induce oxidative stress in bacteria and mammalian cells. *Nanomaterials*, 12(14), 2402.

Chakraborty, N., Jha, D., Roy, I., Kumar, P., Gaurav, S.S., Marimuthu, K., Ng, O.T., Lakshminarayanan, R., Verma, N.K. and Gautam, H.K., (2022). Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies. Journal of nanobiotechnology, 20(1), p.375.

Chen, J., Zhang, Y., Luo, X., Zeng, Y., Xiao, P., Ding, X., Qiu, S., Li, Q., Deng, Q., Wang, S. and Lin, R., (2025). Nanotherapies based on bacterial metabolism: Mechanisms, design and application. *Materials Today Bio*, p.102117.

Gao, W., Chen, Y., Zhang, Y., Zhang, Q., & Zhang, L. (2018). Nanoparticle-based local antimicrobial drug delivery. *Advanced drug delivery reviews*, 127, 46-57.

Hofer, S., Hofstätter, N., Punz, B., Hasenkopf, I., Johnson, L., & Himly, M. (2022). Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 14(6), e1804.

Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024). Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment. *Signal Transduction and Targeted Therapy*, 9(1), 34.

Jain, A., & Bhise, K. (2025). Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications. *Xenobiotica*, 1-12.

Jiang, H., Li, L., Li, Z., & Chu, X. (2024). Metal-based nanoparticles in antibacterial application in biomedical field: Current development and potential mechanisms. *Biomedical microdevices*, *26*(1), 12. https://doi.org/10.1007/s10544-023-00686-8

Landsiedel, R., Hahn, D., Ossig, R., Ritz, S., Sauer, L., Buesen, R., Rehm, S., Wohlleben, W., Groeters, S., Strauss, V. and Sperber, S., (2022). Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects. Particle and fibre toxicology, 19(1), p.21.

Lee, N. Y., Ko, W. C., & Hsueh, P. R. (2019). Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. *Frontiers in pharmacology*, 10, 1153.

Mathur, P., Jha, S., Ramteke, S., & Jain, N. K. (2018). Pharmaceutical aspects of silver nanoparticles. *Artificial cells, nanomedicine, and biotechnology*, *46*(sup1), 115–126. https://doi.org/10.1080/21691401.2017.1414825.

Mazur, P., Skiba-Kurek, I., Mrowiec, P., Karczewska, E., & Drożdż, R. (2020). Synergistic ROS-associated antimicrobial activity of silver nanoparticles and gentamicin against staphylococcus epidermidis. *International journal of nanomedicine*, 3551-3562.

Min, Y., Suminda, G. G. D., Heo, Y., Kim, M., Ghosh, M., & Son, Y. O. (2023). Metal-based nanoparticles and their relevant consequences on cytotoxicity cascade and induced oxidative stress. *Antioxidants*, 12(3), 703.

Mishra, A., Pradhan, D., Halder, J., Biswasroy, P., Rai, V.K., Dubey, D., Kar, B., Ghosh, G. and Rath, G., 2022. Metal nanoparticles against multi-drug-resistance bacteria. *Journal of inorganic biochemistry*, 237, p.111938.

Mondal, S. K., Chakraborty, S., Manna, S., & Mandal, S. M. (2024). Antimicrobial nanoparticles: current landscape and future challenges. *RSC Pharmaceutics*, 1(3), 388-402.

Moreno Ruiz, Y. P., de Almeida Campos, L. A., Alves Agreles, M. A., Galembeck, A., & Macário Ferro Cavalcanti, I. (2023). Advanced hydrogels combined with silver and gold nanoparticles against antimicrobial resistance. *Antibiotics,* 12(1), 104.

Mu, H., Tang, J., Liu, Q., Sun, C., Wang, T., & Duan, J. (2016). Potent Antibacterial Nanoparticles against Biofilm and Intracellular Bacteria. *Scientific reports*, *6*, 18877. https://doi.org/10.1038/srep18877.

Olawade, D. B., Wada, O. Z., Fapohunda, O., Egbewole, B. I., Ajisafe, O., & Ige, A. O. (2024). Nanoparticles for microbial control in water: mechanisms, applications, and ecological implications. *Frontiers in Nanotechnology*, 6, 1427843.

Parvin, N., Joo, S. W., & Mandal, T. K. (2025). Nanomaterial-based strategies to combat antibiotic resistance: mechanisms and applications. Antibiotics, 14(2), 207.

Perez, L., Scarcello, E., Ibouraadaten, S., Yakoub, Y., Leinardi, R., Ambroise, J., Bearzatto, B., Gala, J.L., Paquot, A., Muccioli, G.G. and Bouzin, C., (2021). Dietary nanoparticles alter the composition and function of the gut microbiota in mice at dose levels relevant for human exposure. Food and Chemical Toxicology, 154, p.112352.

Qais, F. A., Ahmad, I., Altaf, M., Manoharadas, S., Al-Rayes, B. F., Abuhasil, M. S. A., & Almaroai, Y. A. (2021). Biofabricated silver nanoparticles exhibit broad-spectrum antibiofilm and antiquorum sensing activity against Gram-negative bacteria. *RSC advances*, 11(23), 13700-13710.

Ribeiro, A. I., Dias, A. M., & Zille, A. (2022). Synergistic effects between metal nanoparticles and commercial antimicrobial agents: a review. *ACS Applied Nano Materials*, 5(3), 3030-3064.

Sakthi Devi, R., Girigoswami, A., Siddharth, M., & Girigoswami, K. (2022). Applications of Gold and Silver Nanoparticles in Theranostics. *Applied biochemistry and biotechnology*, *194*(9), 4187–4219. https://doi.org/10.1007/s12010-022-03963-z.

Sharmin, S., Rahaman, M. M., Sarkar, C., Atolani, O., Islam, M. T., & Adeyemi, O. S. (2021). Nanoparticles as antimicrobial and antiviral agents: A literature-based perspective study. *Heliyon*, 7(3).

Sun, C., Hu, K., Mu, D., Wang, Z., & Yu, X. (2022). The widespread use of nanomaterials: the effects on the function and diversity of environmental microbial communities. *Microorganisms,* 10(10), 2080.

Vivekanandan, K. E., Kumar, P. V., Jaysree, R. C., & Rajeshwari, T. (2025). Exploring molecular mechanisms of drug resistance in bacteria and progressions in CRISPR/Cas9-based genome expurgation solutions. *Global Medical Genetics*, 100042.

Wang, C., Wei, X., Zhong, L., Chan, C. L., Li, H., & Sun, H. (2025). Metal-based approaches for the fight against antimicrobial resistance: Mechanisms, opportunities, and challenges. *Journal of the American Chemical Society*, 147(15), 12361-12380.

Wang, L., Hu, C., & Shao, L. (2017). The antimicrobial activity of nanoparticles: present situation and prospects for the future. *International journal of nanomedicine*, 1227-1249.

Wang, S., Gao, M., Ma, B., Xi, M., & Kong, F. (2020). Size-dependent effects of ZnO nanoparticles on performance, microbial enzymatic activity and extracellular polymeric substances in sequencing batch reactor. *Environmental pollution (Barking, Essex : 1987)*, *257*, 113596. https://doi.org/10.1016/j.envpol.2019.113596.

Xuan, L., Ju, Z., Skonieczna, M., Zhou, P. K., & Huang, R. (2023). Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. *MedComm*, 4(4), e327.

Yu, Z., Li, Q., Wang, J., Yu, Y., Wang, Y., Zhou, Q., & Li, P. (2020). Reactive oxygen species-related nanoparticle toxicity in the biomedical field. *Nanoscale research letters*, 15(1), 115.